TRACON Pharmaceuticals (NASDAQ: TCON) today presented updated data from the Company’s Phase 1b/2 study of TRC105 and Votrient® (pazopanib) in ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE